Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...
News Medical on MSN3d
Antibody-Based Therapy Shows Promise Against Lethal Fungal Infection
Early tests suggest that an antibody-based therapy is safe, with no harmful effects on healthy cells, suggesting that it ...
Antibody-based therapy is several steps closer to treat lethal mucormycosis
Mucormycosis, a fungal infection caused by Mucorales, has high mortality rates in people with weakened immune systems and ...
Devdiscourse5d
Breakthrough in Treating Mucormycosis: Novel Monoclonal Antibody Shows Promising Results
Mucormycosis, a life-threatening fungal infection with high mortality rates, has seen a glimmer of hope through research by ...
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
health.economictimes.indiatimes4d
Antibody-based therapy several notches closer to treat lethal mucormycosis: Study
"Our humanized monoclonal antibody allows antifungal drug therapy to reach to infected tissues because it prevents fungal cells from damaging human cells and blood vessels," Ibrahim said.